Firstly, they reported that the platelet APP ratio (i.e., the percentage of 120–130 kDa to 110 kDa isoforms of the APP) is significantly decreased in the peripheral blood of AD patients compared with controls and proposed to utilise this parameter as a clinical biomarker for the diagnosis of AD. The gene discussed is APP; the disease is Alzheimer disease.